Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431507 | 0.91 | CA2 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4202231 | 0.91 | CA2 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4202226 | 0.91 | CA2 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL13104829 | 0.90 | STAT3 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL9756774 | 0.90 | STAT3 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4383356 | 0.90 | CA2 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4383361 | 0.90 | CA2 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL9756838 | 0.90 | STAT3 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL15607874 | 0.90 | GBA1 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8105088 | 0.90 | STAT3 (0.40) | GAASTAT3ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20170137550-A1 | BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS | DOW GLOBAL TECHNOLOGIES LLC | 2017-05-18 | — | — | US | disclosed |
| WO-2016014749-A1 | BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-9240614-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2579377-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1971598-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007061670-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | GAA 37/4885STAT3 4701/4885ALDH1A1 2461/4885 |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | TP53, CASP3, BAX | GAA 617/4885STAT3 753/4885ALDH1A1 338/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | GAA 37/4885STAT3 4701/4885ALDH1A1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.